Bimekizumab ELISA Kit (KDH28802)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Bimekizumab is an investigational humanized IgG1 monoclonal antibody in development for the treatment of moderate to severe plaque psoriasis in adults. Bimekizumab is designed to selectively and directly inhibit both IL-17A and IL-17F, two key cytokines driving the inflammatory process in plaque psoriasis.